AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27645318 — intervention group
Group type: EXPERIMENTAL
Intervention: XG/CS
Number of subjects: 148
Study 27645318 — intervention group
Group type: COMPARATOR
Intervention: PEG/PG
Number of subjects: 148
Study 25307414 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium (IND/GLY)
Number of subjects: 0
Study 22172965 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal CPAP (4cmH(2)O)
Number of subjects: 12
Study 22172965 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP (4cmH(2)O)
Number of subjects: 12
Study 22172965 — intervention group
Group type: COMPARATOR
Intervention: Baseline (no treatment)
Number of subjects: 12
Study 20668444 — intervention group
Group type: EXPERIMENTAL
Intervention: Noscapine
Number of subjects: 12
Study 20668444 — intervention group
Group type: COMPARATOR
Intervention: Glucosamine
Number of subjects: 12
Study 18979928 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-selected music
Number of subjects: 30
Study 18979928 — intervention group
Group type: COMPARATOR
Intervention: Control (nonmusic group)
Number of subjects: 30
Study 15742449 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac/misoprostol
Number of subjects: 173
Study 15742449 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 173
Study 15742449 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference ratings
Number of subjects: 173
Study 12519045 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean section under general anaesthesia (Group 3)
Number of subjects: 96
Study 12519045 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean section with epidural anaesthesia (Group 2)
Number of subjects: 96
Study 12519045 — intervention group
Group type: COMPARATOR
Intervention: Vaginal delivery (Group 1)
Number of subjects: 96
Study 10365287 — intervention group
Group type: EXPERIMENTAL
Intervention: Inogatran (low dose)
Number of subjects: 320
Study 10365287 — intervention group
Group type: EXPERIMENTAL
Intervention: Inogatran (medium dose)
Number of subjects: 320
Study 10365287 — intervention group
Group type: EXPERIMENTAL
Intervention: Inogatran (high dose)
Number of subjects: 320
Study 10365287 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 320
Study 10365287 — intervention group
Group type: EXPERIMENTAL
Intervention: Inogatran (all doses)
Number of subjects: 320
Study 7497776 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine (1 mg.kg‐1.min‐1)
Number of subjects: 25
Study 7497776 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (2.5 mg.kg‐1.min‐1)
Number of subjects: 25
Study 7497776 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (0.9%)
Number of subjects: 25
Study 1674295 — intervention group
Group type: EXPERIMENTAL
Intervention: Desferrioxamine (125 mg intramuscularly twice daily, 5 days per week, for 24 months)
Number of subjects: 48
Study 1674295 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo (lecithin)
Number of subjects: 48
Study 1674295 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 48
Study 7178257 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat exposure session A (48 degrees C, 34 Torr, 80 min)
Number of subjects: 7
Study 7178257 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat exposure session B (55 degrees C, 15 Torr, 120 min)
Number of subjects: 7
Study 7178257 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat exposure session C (48 degrees C, 15 Torr, 180 min)
Number of subjects: 7
Study 7178257 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily exposures to hot and humid conditions (D: 43 degrees C, 32 Torr, 165 min)
Number of subjects: 7
Study 7178257 — intervention group
Group type: COMPARATOR
Intervention: Control session (thermoneutral climate: 28 degrees C, 10.5 Torr)
Number of subjects: 7
Study 31786991 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) training for 6 weeks in a simulation laboratory
Number of subjects: 24
Study 31786991 — intervention group
Group type: COMPARATOR
Intervention: Conventional preparatory materials
Number of subjects: 24
Study 31786991 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) training
Number of subjects: 24
Study 28012036 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (3 × 5 min bilateral upper thigh ischemia)
Number of subjects: 18
Study 28012036 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 18
Study 27140804 — intervention group
Group type: EXPERIMENTAL
Intervention: New presentation of moroctocog alfa (3,000 IU in a dual-chamber syringe)
Number of subjects: 16
Study 27140804 — intervention group
Group type: COMPARATOR
Intervention: Combined contents of approved 1,000 and 2,000 IU vials
Number of subjects: 16
Study 27140804 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (dual-chamber syringe and combined vials)
Number of subjects: 16
Study 23861242 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea and phlebotomy
Number of subjects: 133
Study 23861242 — intervention group
Group type: COMPARATOR
Intervention: Chronic blood transfusion and iron chelation
Number of subjects: 133
Study 21899583 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotical (synbiotic food supplement)
Number of subjects: 111
Study 21899583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 19476175 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoButton femoral fixation
Number of subjects: 36
Study 19476175 — intervention group
Group type: COMPARATOR
Intervention: Bone plug placed at the aperture of the femoral tunnel
Number of subjects: 36
Study 16397875 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 25
Study 16397875 — intervention group
Group type: COMPARATOR
Intervention: Pressure support ventilation plus volume guarantee (PSV + VG)
Number of subjects: 25
Study 15134183 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir 600 mg + Ritonavir 100 mg twice daily
Number of subjects: 16
Study 15134183 — intervention group
Group type: COMPARATOR
Intervention: Indinavir 400 mg + Ritonavir 100 mg twice daily
Number of subjects: 16
Study 11487446 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 0
Study 9254875 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections (monophasic in 9 patients, biphasic in 5 patients)
Number of subjects: 14
Study 9254875 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections (biphasic)
Number of subjects: 14
Study 9254875 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined functional score from physicians, therapists, and parents
Number of subjects: 14
Study 8015885 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid (50 mg, 3.7 +/- 0.9 mg/kg)
Number of subjects: 79
Study 8015885 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (100 mg, 7.7 +/- 1.7 mg/kg)
Number of subjects: 79
Study 3619710 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting propranolol (160 mg/d)
Number of subjects: 10
Study 3619710 — intervention group
Group type: COMPARATOR
Intervention: Primidone (250 mg at night)
Number of subjects: 10
Study 3619710 — intervention group
Group type: COMPARATOR
Intervention: Clonazepam (4 mg/d)
Number of subjects: 10
Study 30075490 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus intervention (adherence education, reinforcement and monitoring) in HIV group
Number of subjects: 238
Study 30075490 — intervention group
Group type: COMPARATOR
Intervention: Local standard care (controls) in HIV group
Number of subjects: 238
Study 30075490 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus intervention (adherence education, reinforcement and monitoring) in TBM group
Number of subjects: 238
Study 30075490 — intervention group
Group type: COMPARATOR
Intervention: Local standard care (controls) in TBM group
Number of subjects: 238
Study 27145035 — intervention group
Group type: EXPERIMENTAL
Intervention: 72 hour stroke care bundle (intervention group)
Number of subjects: 127
Study 25914482 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual distraction (silent movie using a head-mounted display)
Number of subjects: 60
Study 25914482 — intervention group
Group type: COMPARATOR
Intervention: Control (only wearing the display)
Number of subjects: 60
Study 23832723 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment plus Simvastatin (combination group)
Number of subjects: 80
Study 23832723 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 80
Study 23832723 — intervention group
Group type: COMPARATOR
Intervention: Normal group (healthy persons)
Number of subjects: 80
Study 20494267 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine hydrochloride + MI/CBT
Number of subjects: 70
Study 20494267 — intervention group
Group type: COMPARATOR
Intervention: Placebo + MI/CBT
Number of subjects: 70
Study 18208570 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a (90 or 180 mug/week)
Number of subjects: 184
Study 18208570 — intervention group
Group type: EXPERIMENTAL
Intervention: interferon alfa-2a (3 million units three times weekly)
Number of subjects: 184
Study 18208570 — intervention group
Group type: COMPARATOR
Intervention: nonresponders
Number of subjects: 184
Study 15116906 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm vertical compaction of gutta-percha (G2)
Number of subjects: 32
Study 15116906 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermafil system (G3)
Number of subjects: 32
Study 15116906 — intervention group
Group type: COMPARATOR
Intervention: Lateral condensation (G1)
Number of subjects: 32
Study 11842899 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat-plane stabilization occlusal device
Number of subjects: 11
Study 11842899 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic occlusal device
Number of subjects: 11
Study 11842899 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 11
Study 9669005 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 80
Study 9669005 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 80
Study 9669005 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 80
Study 9669005 — intervention group
Group type: COMPARATOR
Intervention: Total Intravenous Anaesthesia (TIVA)
Number of subjects: 80
Study 8002087 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone and teicoplanin
Number of subjects: 97
Study 8002087 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime and teicoplanin
Number of subjects: 97
Study 8002087 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone and teicoplanin with netilmicin
Number of subjects: 97
Study 8002087 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime and teicoplanin with netilmicin
Number of subjects: 97
Study 3353874 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen for 10 minutes before exercise
Number of subjects: 20
Study 3353874 — intervention group
Group type: COMPARATOR
Intervention: Compressed air for 10 minutes before exercise
Number of subjects: 20
Study 31197340 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator (tPA)
Number of subjects: 0
Study 31197340 — intervention group
Group type: COMPARATOR
Intervention: Endovascular thrombectomy (MT)
Number of subjects: 0
Study 28364678 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) and individualized rehabilitation
Number of subjects: 128
Study 28364678 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NMES)
Number of subjects: 128
Study 25725564 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic steroid (ITS) initial treatment (ITSi)
Number of subjects: 70
Study 25725564 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 70
Study 25725564 — intervention group
Group type: COMPARATOR
Intervention: Systemic steroid treatment
Number of subjects: 70
Study 25725564 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic salvage treatment (ITSs)
Number of subjects: 70
Study 25725564 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including ITSi, combined, systemic, and ITSs)
Number of subjects: 70
Study 24237360 — intervention group
Group type: EXPERIMENTAL
Intervention: ED group (experienced dentists)
Number of subjects: 74
Study 21584345 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Assessment of the Dysexecutive Syndrome
Number of subjects: 41
Study 21584345 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Six Elements - adapted (general index)
Number of subjects: 41
Study 19574328 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacological interventions
Number of subjects: 344
Study 19574328 — intervention group
Group type: EXPERIMENTAL
Intervention: General medical journals
Number of subjects: 344
Study 19574328 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials published after 2000
Number of subjects: 344
Study 19574328 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall trial quality
Number of subjects: 344
Study 19574328 — intervention group
Group type: EXPERIMENTAL
Intervention: High impact factor journals
Number of subjects: 344
Study 16847412 — intervention group
Group type: EXPERIMENTAL
Intervention: Uridine-enriched food supplement NucleomaxX
Number of subjects: 0
Study 16847412 — intervention group
Group type: EXPERIMENTAL
Intervention: NucleomaxX supplementation
Number of subjects: 0
Study 14657844 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids
Number of subjects: 0
Study 14657844 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical calcineurin inhibitors
Number of subjects: 0
Study 14657844 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy and early intervention
Number of subjects: 0
Study 11464618 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for Helicobacter pylori infection
Number of subjects: 0
Study 9460034 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 20
Study 9460034 — intervention group
Group type: COMPARATOR
Intervention: Traditional neuroleptics
Number of subjects: 20
Study 8455665 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (n = 85)
Number of subjects: 165
Study 8455665 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone plus metoclopramide (n = 80)
Number of subjects: 165
Study 3940358 — intervention group
Group type: EXPERIMENTAL
Intervention: Orotracheal intubation (OT)
Number of subjects: 91
Study 3940358 — intervention group
Group type: COMPARATOR
Intervention: Nasotracheal intubation (NT)
Number of subjects: 91
Study 30547305 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flexion TKA implant
Number of subjects: 103
Study 30547305 — intervention group
Group type: COMPARATOR
Intervention: Standard TKA implant
Number of subjects: 103
Study 30547305 — intervention group
Group type: EXPERIMENTAL
Intervention: Both implant designs
Number of subjects: 103
Study 29763676 — intervention group
Group type: EXPERIMENTAL
Intervention: Real dual-tDCS (anodal over the lesioned hemisphere, cathodal over the non-lesioned hemisphere) at 2-mA intensity for 20 minutes followed by conventional physical therapy
Number of subjects: 19
Study 29763676 — intervention group
Group type: COMPARATOR
Intervention: Sham dual-tDCS followed by conventional physical therapy
Number of subjects: 19
Study 29763676 — intervention group
Group type: EXPERIMENTAL
Intervention: Real dual-tDCS
Number of subjects: 19
Study 29763676 — intervention group
Group type: EXPERIMENTAL
Intervention: Real dual-tDCS and conventional physical therapy
Number of subjects: 19
Study 26577796 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 2739
Study 26577796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2739
Study 24662947 — intervention group
Group type: EXPERIMENTAL
Intervention: E10A plus chemotherapy (cisplatin and paclitaxel)
Number of subjects: 136
Study 22664749 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil 600 mg
Number of subjects: 217
Study 22664749 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil 1200 mg
Number of subjects: 217
Study 22664749 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil 1800 mg
Number of subjects: 217
Study 22664749 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil 2400 mg
Number of subjects: 217
Study 22664749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 20398258 — intervention group
Group type: EXPERIMENTAL
Intervention: New colour-coded blood pressure diary
Number of subjects: 138
Study 20398258 — intervention group
Group type: COMPARATOR
Intervention: Conventional blood pressure diary
Number of subjects: 138
Study 17549429 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation (REH)
Number of subjects: 44
Study 17549429 — intervention group
Group type: COMPARATOR
Intervention: Medication (MED) (oxybutynin ER)
Number of subjects: 44
Study 17549429 — intervention group
Group type: EXPERIMENTAL
Intervention: Both REH and MED
Number of subjects: 44
Study 15766372 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical approach
Number of subjects: 10
Study 15766372 — intervention group
Group type: COMPARATOR
Intervention: Macrosurgical approach
Number of subjects: 10
Study 12003160 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (5mg)
Number of subjects: 12
Study 12003160 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 12
Study 12003160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9797978 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment combining two therapies
Number of subjects: 38
Study 9797978 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment designed to mimic experimental treatment
Number of subjects: 38
Study 8106774 — intervention group
Group type: EXPERIMENTAL
Intervention: GenHevac B vaccine (G), 20 micrograms/dose
Number of subjects: 120
Study 8106774 — intervention group
Group type: COMPARATOR
Intervention: Hevac B vaccine (H), 5 micrograms/dose
Number of subjects: 120
Study 8106774 — intervention group
Group type: EXPERIMENTAL
Intervention: GenHevac B vaccine (G), after booster at month 12
Number of subjects: 120
Study 8106774 — intervention group
Group type: COMPARATOR
Intervention: Hevac B vaccine (H), after booster at month 12
Number of subjects: 120
Study 2698453 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg fluspirilene
Number of subjects: 106
Study 2698453 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg fluspirilene
Number of subjects: 106
Study 2698453 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg fluspirilene
Number of subjects: 106
Study 4549500 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent acetone‐inactivated typhoid vaccine by jet injection
Number of subjects: 0
Study 4549500 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat‐killed TAB by jet injection
Number of subjects: 0
Study 4549500 — intervention group
Group type: COMPARATOR
Intervention: Conventional syringe injection
Number of subjects: 0
Study 4549500 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines (monovalent acetone‐inactivated typhoid vaccine and heat‐killed TAB)
Number of subjects: 0
Study 4549500 — intervention group
Group type: EXPERIMENTAL
Intervention: Second jet injection 5 weeks after the first
Number of subjects: 0
Study 31705728 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasuki-style posture supporter
Number of subjects: 50
Study 31705728 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list
Number of subjects: 50
Study 31431378 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (NCRT) plus surgery
Number of subjects: 0
Study 31431378 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 29231496 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with auricular point sticking therapy
Number of subjects: 60
Study 29231496 — intervention group
Group type: COMPARATOR
Intervention: Medication group (20 mg paroxetine hydrochloride once a day for 8 weeks)
Number of subjects: 60
Study 24590412 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered, school-based intervention including a 13-week behavioral parenting intervention and concurrent group for children.
Number of subjects: 1050
Study 24590412 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered, school-based intervention for highest-risk families.
Number of subjects: 1050
Study 24590412 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered, school-based intervention for boys at high risk for problems based on baseline behavioral dysregulation.
Number of subjects: 1050
Study 24590412 — intervention group
Group type: COMPARATOR
Intervention: Pre-kindergarten education as usual (control condition).
Number of subjects: 1050
Study 23359575 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Start program
Number of subjects: 443
Study 23359575 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 443
Study 21365053 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthetic abutments with a Morse taper connection and a platform switch (test group)
Number of subjects: 40
Study 21365053 — intervention group
Group type: COMPARATOR
Intervention: Conventional abutments with an internal connection and a matching diameter (control group)
Number of subjects: 40
Study 18758872 — intervention group
Group type: EXPERIMENTAL
Intervention: Transorally introduced circular stapler (SurgASSIST)
Number of subjects: 20
Study 18758872 — intervention group
Group type: COMPARATOR
Intervention: Transabdominal introduced circular stapler (CEEA)
Number of subjects: 20
Study 16864708 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus GG and Bifidobacterium lactis Bb-12)
Number of subjects: 72
Study 16864708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 12640530 — intervention group
Group type: EXPERIMENTAL
Intervention: 48-week group (6 MU of natural IFN-alpha by intramuscular injection three times weekly for 24 weeks)
Number of subjects: 51
Study 12640530 — intervention group
Group type: EXPERIMENTAL
Intervention: 72-week group (6 MU of natural IFN-alpha by intramuscular injection three times weekly for 48 weeks)
Number of subjects: 51
Study 12640530 — intervention group
Group type: EXPERIMENTAL
Intervention: 48-week group
Number of subjects: 51